Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria and Chronic Kidney Disease Biotech Investing
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting Biotech Investing
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation Biotech Investing
Republic Technologies Partners with FalconX to Support Ethereum Validator Operations Medical Device Investing
Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research Medical Device Investing
Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market Biotech Investing
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress Biotech Investing
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies Biotech Investing
